Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1989
|
| gptkbp:ATCCode |
M01AB15
|
| gptkbp:contraindication |
peptic ulcer
renal impairment history of GI bleeding |
| gptkbp:drugClass |
nonsteroidal anti-inflammatory drug
|
| gptkbp:genericName |
gptkb:ketorolac
|
| gptkbp:halfLife |
4-6 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Toradol
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Roche
|
| gptkbp:maximumDurationOfUse |
5 days
|
| gptkbp:mechanismOfAction |
COX inhibitor
|
| gptkbp:notRecommendedFor |
chronic pain
pediatric patients under 2 years |
| gptkbp:pregnancyCategory |
C (prior to 30 weeks gestation)
D (after 30 weeks gestation) |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:riskFactor |
increased risk of cardiovascular events
increased risk of gastrointestinal bleeding |
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
nausea
headache gastrointestinal bleeding drowsiness renal impairment |
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:ketorolac
|
| gptkbp:bfsLayer |
7
|